Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1
Background. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endo...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2021/8867218 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524535286824960 |
|---|---|
| author | Xiaowen Hu Mengsiyu Li Chunxue Zhang Shuguang Pang |
| author_facet | Xiaowen Hu Mengsiyu Li Chunxue Zhang Shuguang Pang |
| author_sort | Xiaowen Hu |
| collection | DOAJ |
| description | Background. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endobiotic compounds to accelerate drug excretion. Herein, we designed experiments to investigate the effects and mechanisms of metformin on SULT2A1 expression in vitro. Methods. The hepatocellular carcinoma cell line, HepaRG, was cultured with different concentrations of metformin. The cell viability was measured using CCK8 kit. HepaRG was used to evaluate the protein expression of pregnane X receptor (PXR), the constitutive androstane receptor (CAR), SULT2A1, AMP-activated protein kinase (AMPK), and phosphorylation of AMPK (p-AMPK), respectively, at different concentrations of metformin with or without rifampin (human PXR activator) and CITCO (human CAR activator). The coregulators with CAR on SULT2A1 promoter response elements have also been characterized. Results. We showed that metformin did not affect the basic expression of SULT2A1 but could suppress the expression of SULT2A1 induced by the activator of human CAR. Investigations revealed that metformin which could block CAR nuclear translocation further suppress SULT2A1. In addition, we found that the prevented CAR transfer into the nucleus by metformin was partially an AMPK-dependent event. Conclusion. The present study indicated that the activation of AMPK-CAR pathway mediated the suppression of SULT2A1 by metformin. Metformin may affect the metabolism and clearance of drugs which are SULT2A1 substrates. The results that emerged from this work provide substantial insights into an appropriate medication in the treatment of diabetes patients. |
| format | Article |
| id | doaj-art-44f2633899904d979dee0999b30600a4 |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-44f2633899904d979dee0999b30600a42025-02-03T05:52:57ZengWileyInternational Journal of Endocrinology1687-83371687-83452021-01-01202110.1155/2021/88672188867218Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1Xiaowen Hu0Mengsiyu Li1Chunxue Zhang2Shuguang Pang3Department of Endocrinology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaDepartment of Ultrasound, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Nuclear Medicine, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, ChinaDepartment of Endocrinology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, ChinaBackground. Metformin, as a first-line treatment for diabetes, interacts with many protein kinases and transcription factors which affect the expression of downstream target genes governing drug metabolism. Sulfotransferase, SULT2A1, one phase II metabolic enzyme, sulfonates both xenobiotic and endobiotic compounds to accelerate drug excretion. Herein, we designed experiments to investigate the effects and mechanisms of metformin on SULT2A1 expression in vitro. Methods. The hepatocellular carcinoma cell line, HepaRG, was cultured with different concentrations of metformin. The cell viability was measured using CCK8 kit. HepaRG was used to evaluate the protein expression of pregnane X receptor (PXR), the constitutive androstane receptor (CAR), SULT2A1, AMP-activated protein kinase (AMPK), and phosphorylation of AMPK (p-AMPK), respectively, at different concentrations of metformin with or without rifampin (human PXR activator) and CITCO (human CAR activator). The coregulators with CAR on SULT2A1 promoter response elements have also been characterized. Results. We showed that metformin did not affect the basic expression of SULT2A1 but could suppress the expression of SULT2A1 induced by the activator of human CAR. Investigations revealed that metformin which could block CAR nuclear translocation further suppress SULT2A1. In addition, we found that the prevented CAR transfer into the nucleus by metformin was partially an AMPK-dependent event. Conclusion. The present study indicated that the activation of AMPK-CAR pathway mediated the suppression of SULT2A1 by metformin. Metformin may affect the metabolism and clearance of drugs which are SULT2A1 substrates. The results that emerged from this work provide substantial insights into an appropriate medication in the treatment of diabetes patients.http://dx.doi.org/10.1155/2021/8867218 |
| spellingShingle | Xiaowen Hu Mengsiyu Li Chunxue Zhang Shuguang Pang Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 International Journal of Endocrinology |
| title | Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 |
| title_full | Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 |
| title_fullStr | Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 |
| title_full_unstemmed | Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 |
| title_short | Constitutive Androstane Receptor-Mediated Inhibition of Metformin on Phase II Metabolic Enzyme SULT2A1 |
| title_sort | constitutive androstane receptor mediated inhibition of metformin on phase ii metabolic enzyme sult2a1 |
| url | http://dx.doi.org/10.1155/2021/8867218 |
| work_keys_str_mv | AT xiaowenhu constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1 AT mengsiyuli constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1 AT chunxuezhang constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1 AT shuguangpang constitutiveandrostanereceptormediatedinhibitionofmetforminonphaseiimetabolicenzymesult2a1 |